Search

Your search keyword '"Bryant, Richard J."' showing total 13 results
Start Over Author "Bryant, Richard J." Publisher wiley
13 results on '"Bryant, Richard J."'

4. Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial

Author

Sooriakumaran, Prasanna, primary, Wilson, Caroline, additional, Rombach, Ines, additional, Hassanali, Neelam, additional, Aning, Jonathan, additional, D. Lamb, Alastair, additional, Cathcart, Paul, additional, Eden, Christopher, additional, Ahmad, Imran, additional, Rajan, Prabhakar, additional, Sridhar, Ashwin, additional, Bryant, Richard J., additional, Elhage, Oussama, additional, Cook, Jonathan, additional, Leung, Hing, additional, Soomro, Naeem, additional, Kelly, John, additional, Nathan, Senthil, additional, Donovan, Jenny L., additional, and Hamdy, Freddie C., additional

Published
2022
Full Text
View/download PDF

5. Local anaesthetic transperineal (LATP) prostate biopsy using a probe‐mounted transperineal access system: a multicentre prospective outcome analysis

Author

Lopez, J. Francisco, primary, Campbell, Angus, additional, Omer, Altan, additional, Stroman, Luke, additional, Bondad, Jasper, additional, Austin, Tom, additional, Reeves, Thomas, additional, Phelan, Curtis, additional, Leiblich, Aaron, additional, Philippou, Yiannis, additional, Lovegrove, Catherine E., additional, Ranasinha, Nithesh, additional, Bryant, Richard J., additional, Leslie, Tom, additional, Hamdy, Freddie C., additional, Brewster, Simon, additional, Bell, C. Richard, additional, Popert, Rick, additional, Hodgson, Dominic, additional, Elsaghir, Mohammed, additional, Eddy, Ben, additional, Bolomytis, Stefanos, additional, Persad, Raj, additional, Reddy, Utsav D., additional, Foley, Charlotte, additional, Rij, Simon, additional, Lam, Wayne, additional, and Lamb, Alastair D., additional

Published
2021
Full Text
View/download PDF

6. Ductal adenocarcinoma of the prostate: A systematic review and meta‐analysis of incidence, presentation, prognosis, and management

Author

Ranasinha, Nithesh, primary, Omer, Altan, additional, Philippou, Yiannis, additional, Harriss, Eli, additional, Davies, Lucy, additional, Chow, Ken, additional, Chetta, Paolo M., additional, Erickson, Andrew, additional, Rajakumar, Timothy, additional, Mills, Ian G., additional, Bryant, Richard J., additional, Hamdy, Freddie C., additional, Murphy, Declan G., additional, Loda, Massimo, additional, Hovens, Christopher M., additional, Corcoran, Niall M., additional, Verrill, Clare, additional, and Lamb, Alastair D., additional

Published
2021
Full Text
View/download PDF

7. Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit – the ‘Fry‐Turnbull’ effect

Author

Lovegrove, Catherine E., primary, Musbahi, Omar, additional, Ranasinha, Nithesh, additional, Omer, Altan, additional, Lopez, Francisco, additional, Campbell, Angus, additional, Bryant, Richard J., additional, Leslie, Tom, additional, Bell, Richard, additional, Brewster, Simon, additional, Hamdy, Freddie C., additional, Wright, Ben, additional, and Lamb, Alastair D., additional

Published
2020
Full Text
View/download PDF

8. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy

Author

Wu, Xiaoning, primary, Scott, Helen, additional, Carlsson, Sigrid V., additional, Sjoberg, Daniel D., additional, Cerundolo, Lucia, additional, Lilja, Hans, additional, Prevo, Remko, additional, Rieunier, Guillaume, additional, Macaulay, Valentine, additional, Higgins, Geoffrey S., additional, Verrill, Clare L., additional, Lamb, Alastair D., additional, Cunliffe, Vincent T., additional, Bountra, Chas, additional, Hamdy, Freddie C., additional, and Bryant, Richard J., additional

Published
2019
Full Text
View/download PDF

11. Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?

Author

Bryant, Richard J., primary, Yang, Bob, additional, Philippou, Yiannis, additional, Lam, Karla, additional, Obiakor, Maureen, additional, Ayers, Jennifer, additional, Chiocchia, Virginia, additional, Gleeson, Fergus, additional, MacPherson, Ruth, additional, Verrill, Clare, additional, Sooriakumaran, Prasanna, additional, Hamdy, Freddie C., additional, and Brewster, Simon F., additional

Published
2018
Full Text
View/download PDF

13. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

Author

Bryant, RJ, Oxley, J, Young, GJ, Lane, JA, Metcalfe, C, Davis, M, Turner, EL, Martin, RM, Goepel, JR, Varma, M, Griffiths, DF, Grigor, K, Mayer, N, Warren, AY, Bhattarai, S, Dormer, J, Mason, M, Staffurth, J, Walsh, E, Rosario, DJ, F Catto, JW, Neal, DE, Donovan, JL, Hamdy, FC, Protect Study Group, Bollina, P, Doble, A, Doherty, A, Gillatt, D, Gnanapragasam, V, Hughes, O, Kockelbergh, R, Kynaston, H, Paul, A, Paez, E, Rowe, E, Group, Protect Study, Bryant, Richard J [0000-0002-8330-9251], Oxley, Jon [0000-0002-4348-0273], and Apollo - University of Cambridge Repository

Subjects
Male, medicine.medical_specialty, Time Factors, Urology, Perineural invasion, risk stratification, Risk Assessment, BTC (Bristol Trials Centre), Cohort Studies, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Stable Disease, Prostate, Internal medicine, Humans, Medicine, 030212 general & internal medicine, Stage (cooking), Pathological, Aged, Neoplasm Staging, business.industry, Prostatic Neoplasms, risk‐stratification, Cancer, Middle Aged, Prostate-Specific Antigen, medicine.disease, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cohort, Disease Progression, Kallikreins, BRTC, pathology, business, Follow-Up Studies, Bristol Population Health Science Institute
Abstract

OBJECTIVES: The ProtecT (Prostate testing for cancer and Treatment) trial randomised 1,643 men with localised prostate cancer (PCa) to active monitoring, radical prostatectomy or radical radiotherapy. At 10-year median follow-up there were no differences in mortality between groups, but men receiving radical treatment had their disease progression reduced by half. We tested the hypothesis that the baseline clinico-pathological features of men who progressed (n=198) were different from those with stable disease (n=1,409).PATIENTS AND METHODS: We stratified the participants' cohort at baseline according to risk of progression using clinical disease stage, pathological grade and PSA, using Cox proportional hazard models.RESULTS: The findings demonstrated that 34% (n=505) of men had intermediate or high-risk disease, and 66% (n=973) had low-risk PCa. Of 198 men who progressed, 101 (51%) had baseline International Society of Urological Pathology (ISUP) Grade Group 1, 59 (30%) Grade Group 2, and 38 (19%) Grade Group 3 PCa, compared with 79%, 17% and 5% respectively for 1,409 men without progression (pCONCLUSIONS: We demonstrate that one-third of the ProtecT cohort consists of intermediate / high risk disease, and the outcomes data at an average of 10-years follow-up are generalisable beyond men with low-risk PCa.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results